

**SIMON S. KOGAN**  
ATTORNEY AT LAW  
25 Fanning Street, room 557  
Staten Island, New York 10314  
Tel:(646) 983-0791  
Email: [simonkoganlaw@gmail.com](mailto:simonkoganlaw@gmail.com)

November 28, 2022

OTC Markets Group, Inc.  
304 Hudson Street, Second Floor  
New York, New York 10013

re: Protek Capital, Inc.

Annual Report for the period ended January 31, 2021 and Quarterly report for Q1  
3/31/22, Q2, and Q3

Dear Ladies and Gentlemen:

I have served as counsel for Protek Capital, Inc, (the “Company” ) and have been retained by the Company for the purpose of (i) entering into the Attorney Letter Agreement dated November 22, 2022 (the “Agreement”) and (ii) posting this letter on the OTC Disclosure and News Service in accordance with the Guidelines set forth in the Agreement. OTC Markets Group, Inc. Is entitled to rely on this letter in determining whether the Company has made adequate current information publicly available within the meaning of Rule 144 (c)(2) under the Securities Act of 1933.

In connection with this Letter, I reviewed the Company's Annual Report for the period ended January 21, 2022 (the "Report") posted on the OTC Disclosure and news service on June 14, 2022, the Quarterly report for the period ended April 30, 2022 posted on the OTC Disclosure and News service on June 14, 2022, the Quarterly report for the period ended July 21, 2022 posted on November 25, 2022, and the quarterly report ended October 31, 2022 posted on the OTC markets disclosure and News Service on November 25, 2022. I also reviewed such other corporate records, certificates of officers, certificates of public officials and earlier documents and instruments and such questions of law as I considered necessary or appropriate to require as a basis for the determination expressed herein.

For the purposes of this letter, I assumed (i) the genuineness of all of officers, certificates of public officials, and other documents and instruments submitted to me as originals, (ii) the conformity to authentic originals of all corporate records, certificates, officers, certificates of public officials and other documents submitted to me as certified, conformed, photostatic or facsimile copies thereof and (iii) the accuracy and adequacy of the disclosures made to me by the Company, the Company's management and the Company's board of directors including, without limitation, the financial information contained in the Disclosure Documents (as described below).

I have no reason to believe that such records, certificates or other documents are not accurate, authentic or reliable and I make no assurances as to the accuracy and adequacy of such documents. As counsel to the Company, I have advised the Company as to the requirements of Rule 144 (c) of the Securities Act of 1933, as amended (the "Act") and Rule 15c2-11 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), examined such corporate records and other

documents and such questions of law as counsel considered necessary or appropriate for purposes of rendering this letter, and rendered such other legal advice and assistance in the course of the preparation of the Disclosure Documents as requested by management of the Company and I deemed necessary.

It is my opinion that the reports constitutes adequate current information that is publicly available within the meaning of Rule 144 (c)(2) under the Securities Act of 1933 as a result of the annual report as a result of the Annual report being posted on the OTC Disclosure and News Service on March 21, 2022 and that the Disclosure documents with the Report as filed include all of the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the common stock of the Company under Rule 15 c2-11 under the Securities Exchange Act of 1934, and that the Disclosure Documents appear on their face to comply as to form in all material respects with the Guidelines for Providing Adequate Current Information and have been posted through the OTC Disclosure and News Service.

I have been informed that the preparation of the financial statements contained in the Disclosure Documents, under the direction of Scott Tassan, CFO of the Company. The financial statements contained in the Report are unaudited. The company's transfer agent is Securitize f/k/a Pacific Stock Transfer, Inc. 6725 Via Austin Parkway – Suite 300, Las Vegas, NV 89119 with a telephone number of 800-785-7782, Securitize f/k/a Pacific Corporate Stock Transfer is registered with the Securities Exchange Commission. The Company has confirmed to me that information provided by Securitize f/k/a Pacific Corporate Stock Transfer was used to confirm the number of issued and outstanding shares set forth in the Report. I am a U.S. resident and have (i) personally met via Tele-conference with management and with a majority of the Board of Directors, (ii) reviewed the Disclosure Documents, and (iii) discussed

the Disclosure Documents with management and with a majority of the board if directors of the Company. I have no reason to believe that these individuals are not reliable.

I am a member of the bar of the State of New York. In the past five years, I have not been the subject of any proceeding brought by any regulatory agency, nor has my ability to practice before the Securities Exchange Commission, the CFTC or FINRA ever been suspended.

Based on conversations with management, I am of the opinion that the Company is not now and has never been a shell company as that term is defined in rule 405 promulgated under the Securities Act of 1933 and rule 12b-2 promulgated under the Securities Exchange Act of 1934.

I am licensed to practice law in the state of New York. Accordingly, the foregoing letter applies only insofar as the existing law of the State of New York and applicable federal law may be concerned and I express no opinion with respect to (i) the laws of any other jurisdiction, (ii) choice of law, (iii) conflicts of law, and none of the views stated above shall be deemed to include or refer to the laws of any other jurisdiction, choice of law, conflicts of law and none of the views stated above shall be deemed to include or refer to the laws of any other jurisdiction, choice of law or conflicts of law.

I am permitted to practice before the securities and Exchange Commission and have not been prohibited from practicing before the Securities Exchange Commission. To the best of my knowledge; after inquiry of management neither the Company, nor any 5% or greater holder of the Company's stock, or I acting as corporate counsel to the

Company is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.


As a matter of policy, I do not accept stock in clients as compensation for services rendered or to be rendered. This letter is limited to the matters set forth herein and no opinion may be inferred or implied beyond the matters expressly set forth herein. Except as support was set forth herein, this opinion is being provided solely for the purpose of determining whether the Company has made adequate current information publically available within the meaning of Rule 144 (c)(2) under the Securities Act of 1933, including all of the information that a broker-dealer would be required to obtain from the Company in order to publish a quotation for the Securities under Rule 15 c-211 promulgated under the Securities Exchange Act.

I have personally video-conferenced with Edward Vakser and Jason Perley who represents a majority of the Board and management to discuss the Company's disclosure obligations.

This letter is limited to the matters set forth herein and no opinion may be inferred or implied beyond the matters expressly contained herein. Except as support was set forth herein set forth herein, this opinion is being provided solely for the purpose whether the Company has made adequate information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933, including all of the information that a broker-dealer would be required to obtain from the Company in order to publish a quotation for the Company's securities under Rule 15 c2-11 under the Securities Exchange Act of 1934.

This letter is rendered solely to OTC Markets Group, Inc, in connection with the Agreement, and may not be relied upon by any other person without the express written consent of the undersigned. OTC Markets Group, Inc. May publish this letter on OTC Disclosure and News Service for viewing by the public.

Respectfully Submitted,

A handwritten signature in black ink, appearing to read "Evan Hoffman". The signature is fluid and cursive, with the first name "Evan" written in a larger, more prominent script than the last name "Hoffman".